XML 30 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Cash flows from operating activities:      
Net income (loss) $ 1,141,255 $ 3,733,707 $ (270,342)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      
Depreciation 436,247 495,347 458,734
Amortization 581,386 373,350 14,013
Fair market value adjustment - warrants   (460,289) (85,325)
Exercise and expiration of warrants     (15,145)
Amortization of discounts on investments, net (91,485)    
Stock-based compensation 736,066 298,535 341,554
Forgiveness of note to employee     266,282
Deferred tax liability 1,805 6,166  
Changes in operating assets and liabilities:      
Trade accounts receivable (2,678,746) (1,422,998) 210,140
Inventory (161,972) (27,082) (119,733)
Prepaid expenses and other assets (525,919) (120,567) (36,265)
Accounts payable (101,801) 1,075,534 298,918
Accrued bonus 475,966 413,051 516,409
Accrued liabilities 49,591 411,255 361,067
Deferred obligation under operating lease (117,049) (106,732) (91,482)
Net cash provided by (used in) operating activities (254,656) 4,669,277 1,848,825
Cash flows from investing activities:      
Purchases of available-for-sale securities (21,962,486)    
Maturities of available-for-sale securities 750,000    
Cash paid for acquisition (6,348,730)   (4,000,000)
Purchases of property and equipment (263,063) (275,649) (132,854)
Net cash used in investing activities (27,824,279) (275,649) (4,132,854)
Cash flows from financing activities:      
Proceeds from notes payable     4,000,000
Repayment of notes payable (1,388,563) (1,624,999) (273,175)
Proceeds from initial public offering and issuance of warrants to underwriters   13,600,800  
Costs related to initial public offering 781 (2,657,604)  
Proceeds from secondary public offering   26,797,094  
Costs related to secondary public offering   (820,832)  
Proceeds from exercise of warrants     225,000
Common stock repurchases (1,257,100)    
Proceeds from exercise of stock options 588,482 137,403 77,372
Net cash provided by (used in) financing activities (2,056,400) 35,431,862 4,029,197
Net increase (decrease) in cash and cash equivalents (30,135,335) 39,825,490 1,745,168
Cash and cash equivalents, beginning of period 45,161,403 5,335,913 3,590,745
Cash and cash equivalents, end of period 15,026,068 45,161,403 5,335,913
Supplemental disclosure of cash flow information      
Interest paid 98,711 177,460 39,489
Taxes paid $ 102,819   6,171
Supplemental disclosure of non-cash investing and financing activities:      
Accretion of Series E, F, and G preferred redeemable convertible stock to redemption amount   1,356,707 $ 2,157,549
Conversion of warrants   249,215  
Conversion of preferred stock into common stock   $ 50,432,162